| ID | 1203 |
| Name of the vaccine | InvaplexAR |
| Microbe | Bacteria |
| Disease name | Bacillary Dysentery (Shigellosis) |
| Name of bacteria | Shigella genus |
| Type of vaccine | Recombinant |
| Nucleic acid content | DNA |
| Age | 18 to 45 years |
| Description of the vaccine | Artificial Invaplex vaccine consists of recombinant IpaB, IpaC and wild-type LPS using molar ratios. |
| Name of the manufacturer | U.S. Army Medical Research and Development Command |
| Name of the manufacturing country | United States |
| Year of manufacture | 2016 |
| Clinical Phase status | Clinical - Phase 1 |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Three doses. |
| Mechanism of action | Systemic and mucosal vaccine antigen-specific immune response. |
| Route of administration | Intranasal |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT02445963 |
| Reference | https://www.who.int/immunization/research/meetings_workshops/7.Shigella.Richard_Walker.pdf |
| Other name | NA |
| Additional Links | NA
|